Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Gilead Vs. Merck: What To Know
Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.
Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'
Sovaldi Recent News
Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan
High Drug Prices Put Gilead Under Fire From Senate Committee
Gilead Stock Whiffs, But One Pro Remains Bullish
China Rejects Gilead's Sovaldi Patent Application
Gilead Soothes Price War Worry With Q1 Results
Is Gilead Sciences About To Buy Vertex For $45 Billion?
This Data Offers Insight Into Gilead Sales
Gilead Sciences Hovering Above Major Support Level
Is Gilead's Latest Japan Win Good News For Shareholders?
Gilead Shares Tumble On Drug Warning; Baird Says Buy
Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations
Gilead Sciences' Sovaldi Patent Application Rejected In India
UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'
Markets Close The Week On Negative Note As Ukraine Worries Mount
Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug
Biotechs Struggling To Find A Bottom
Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat
Market Wrap For February 4: Investors And Traders Go Bargain Hunting